Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron (REGN) reported strong Q4 2024 financial results with revenues increasing 10% to $3.79 billion and full-year 2024 revenues up 8% to $14.20 billion. Key highlights include:
- Dupixent global net sales grew 15% to $3.70 billion in Q4 and 22% to $14.15 billion for full year
- Combined EYLEA HD and EYLEA U.S. net sales increased 2% to $1.50 billion in Q4
- Libtayo global net sales rose 50% to $367 million in Q4
The company announced significant shareholder returns including:
- Initiation of $0.88 quarterly dividend program
- Additional $3.0 billion share repurchase authorization, bringing total capacity to ~$4.5 billion
Regulatory submissions were made for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, and other key products. Positive Phase 3 results were reported for EYLEA HD in retinal vein occlusion and Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science have announced the top 40 finalists for the 2025 Regeneron Science Talent Search (STS), America's oldest and most prestigious STEM competition for high school seniors. The competition, now in its 84th year, will award over $1.8 million in prizes, with individual awards ranging from $25,000 to $250,000.
The finalists, selected from 300 scholars and nearly 2,500 total entrants, represent 39 schools across 16 U.S. states. Their research projects cover diverse topics including species migration, crop protection, disease diagnosis using AI, and genetic and cancer therapies. The competition will take place from March 6-12, 2025, in Washington D.C., with the top 10 winners being announced on March 11.
The program's alumni have achieved remarkable success, including 13 Nobel Prizes and 23 MacArthur Fellowships. Each finalist's school receives $2,000 to support math and science programs, demonstrating the competition's commitment to fostering scientific innovation and education.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science announced the top 40 finalists for the 2025 Regeneron Science Talent Search (STS), America's longest-running STEM competition for high school seniors. The finalists, selected from 300 scholars and 2,500 total entrants, represent 39 schools across 16 U.S. states.
The competition, now in its 84th year, will award more than $1.8 million in prizes, with individual awards ranging from $25,000 to $250,000 for the top winner. The finalists will participate in a week-long competition from March 6-12, 2025, featuring rigorous judging and public research presentations.
Research projects span diverse areas including species migration, crop protection, disease diagnosis using AI, and genetic and cancer therapies. The program has a notable track record, with alumni winning 13 Nobel Prizes and 23 MacArthur Fellowships.
Regeneron Pharmaceuticals (REGN) provided key business updates at the J.P. Morgan Healthcare Conference. Dupixent now treats over a million patients globally, with recent approval in COPD. EYLEA HD and EYLEA maintained U.S. anti-VEGF market leadership, achieving $6 billion in combined U.S. net sales for 2024, up 1% year-over-year. Fourth quarter sales reached $1.5 billion.
Libtayo exceeded $1 billion in 2024 sales and demonstrated significant clinical benefits in high-risk CSCC treatment, showing a 68% reduction in disease recurrence risk. The company resubmitted the Linvoseltamab BLA, with launch expected mid-2025. Regeneron's pipeline includes approximately 40 investigational candidates, with advanced programs targeting a market opportunity exceeding $220 billion by 2030.
The company also announced collaboration with Truveta to expand its DNA-linked healthcare database, aiming to sequence up to 10 million additional individuals.
Regeneron Pharmaceuticals (REGN) announced positive results from the Phase 3 C-POST trial of Libtayo® (cemiplimab) for high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery treatment. The trial demonstrated a 68% reduction in disease recurrence or death risk compared to placebo, with a median follow-up of 24 months.
The study enrolled 415 patients, randomized to receive either Libtayo or placebo for up to 48 weeks. Safety analysis showed adverse events in 91% of Libtayo patients versus 89% in placebo group, with Grade ≥3 adverse events occurring in 24% versus 14% respectively. Treatment discontinuations were 10% in the Libtayo arm compared to 1.5% in placebo.
Regeneron plans to submit these results to the FDA in the first half of 2025. Notably, Libtayo is the first immunotherapy to show significant benefit in high-risk CSCC in the adjuvant setting, while a recent Phase 3 trial with Keytruda® failed in the same application.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a strategic collaboration with Truveta, Inc. and its U.S. health systems network, investing $119.5 million in Truveta's Series C financing round. The partnership launches the Truveta Genome Project, which aims to sequence up to ten million additional de-identified patient volunteers with linked electronic health records (EHRs).
The project will expand Regeneron Genetics Center's existing database of nearly three million exomes. RGC will conduct exome sequencing, genotyping, and imputation of the volunteers using biospecimens from Truveta's health system members. This data will integrate with Truveta's medical database, which represents over 120 million patients across 30 health systems.
Illumina, Inc. will also invest $20 million in the financing round. RGC will maintain exclusive rights to perform research-related sequencing on collected samples and access de-identified EHR data from study participants. The collaboration aims to accelerate drug target discovery, optimize clinical trials, and advance healthcare delivery.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the conference call through a webcast on Regeneron's investor relations website. For telephone participation, advance registration is required through a provided link, after which participants will receive confirmation emails with access details. A replay and transcript will be available on the company's website for at least 30 days following the call.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies, REGN7508 and REGN9933, targeting Factor XI for thrombosis control. The trials demonstrated robust antithrombotic effects with no clinically relevant bleeding observed. REGN7508 showed superiority to enoxaparin and non-inferiority to apixaban, while REGN9933 proved non-inferior to enoxaparin in preventing venous thromboembolism after knee surgery.
Key results showed VTE events in 7% of patients for REGN7508, 17% for REGN9933, compared to 21% for enoxaparin and 12% for apixaban. No major bleeding or serious adverse events were reported across all treatment arms. The company plans to initiate Phase 3 trials in 2025.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). Investors and interested parties can access the webcast through Regeneron's website investor section. A replay and transcript will be available on the company's website for at least 30 days after the presentation.
Regeneron Pharmaceuticals (REGN) announced positive Phase 3 QUASAR trial results for EYLEA HD® (aflibercept) Injection 8 mg in treating macular edema following retinal vein occlusion (RVO). The trial met its primary endpoint, demonstrating that EYLEA HD administered every 8 weeks achieved non-inferior vision gains compared to EYLEA® 2 mg monthly dosing.
Key findings at 36 weeks showed mean vision improvements of 17.0-19.1 letters for EYLEA HD groups versus 17.8 letters for EYLEA. Notably, about 90% of EYLEA HD patients maintained 8-week dosing intervals. The safety profile remained consistent with previous trials. Regeneron plans to submit a supplementary biologics license application to the FDA in Q1 2025.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
